Home/Pipeline/Site-specific Antibody-Drug Conjugates

Site-specific Antibody-Drug Conjugates

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Constructive Bio

About Constructive Bio

Constructive Bio is pioneering a dual-technology platform combining whole-genome synthesis and engineered translation to reprogram the genetic code of microorganisms. This enables the scalable, fermentation-based production of peptide and protein therapeutics containing precisely placed non-canonical amino acids, unlocking new chemistries and functions. The company is positioned to create next-generation drug candidates, such as stabilized GLP-1 analogs and site-specific antibody-drug conjugates, with potential advantages in stability, efficacy, and target engagement. Its foundational science is based on peer-reviewed research from Professor Jason Chin's lab.

View full company profile

Therapeutic Areas

Metabolic Disease Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active